Cellbion Co., Ltd

Cellbion Co., Ltd

KKRX:308430
11,180.00
KRW
-160.00
(-1.41%)
591.05EPS
27.78P/E
215.18BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
132.79
42.41
42.9
40.79
157.15
104.21
181.76
148.23
225.64
151.78
167.11
Basic EPS, GAAP
-1,269
-1,334
-910
-410
-351
-543
-658
-366
-716
-591
603.66
Free Cash Flow per Basic Share
-3,368.18
-730.94
-529.73
-464.08
-277.67
-424.87
-532.6
-440.1
-487.17
-563.77
-848.08
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-125.85
-649.69
480.69
205.36
183.77
665.07
214.96
588.55
2,310.37
1,775.83
2,815.62
Tangible Book Value per Share
-178.85
-698.69
406.67
164.51
140.57
616.94
164.26
534.46
2,260.78
1,716.5
2,758.89
Basic Weighted Avg Shares
1
5
7
9
9
9
10
10
10
13
13
Sales/Revenue/Turnover
133
212
311
350
1,361
917
1,763
1,471
2,290
1,945
2,146
Operating Margin (%)
-948.39
-1,051.2
-1,202.42
-1,008.1
-224.69
-496.28
-300.83
-342.79
-311.67
-423.87
-447.16
Depreciation Expense
93
443
654
965
995
983
768
618
625
779
1,176
Net Income, GAAP
-1,269
-6,670
-6,592
-3,518
-3,039
-4,778
-6,382
-3,633
-7,266
-7,574
7,751
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-955.61
-3,145.43
-2,121.13
-1,005.2
-223.36
-521.08
-362.02
-246.92
-317.32
-389.37
361.23
Working Capital
4,193
6,897
4,182
926
1,492
8,019
2,286
7,464
30,504
22,841
67,482
LT Debt
- -
- -
- -
636
528
585
739
577
1,602
7,327
12,443
Total Equity
-1,603
-8,276
6,123
2,616
2,341
8,472
2,738
7,497
29,575
22,787
36,129
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-24.34
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
21.28
Return on Common Equity (%)
- -
- -
- -
-80.5
-122.61
-88.37
-113.86
-70.98
-39.2
-28.93
24.8

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,092
1,208
1,316
LT Borrowings
1,000
900
6,393
LT Finance Leases
6,327
6,219
6,050
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
302,824
402,909
215,184

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
25,103
21,449
69,562
Cash, Cash Equivalents & STI
23,908
20,236
67,651
Accounts Receivable, Net
195
185
367
Inventories
359
311
344
Total Current Liabilities
2,262
1,795
2,080
Payables & Accruals
- -
- -
- -
ST Debt
1,092
1,208
1,316
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
127.91%
-22.95%
Free Cash Flow
- -
27.51%
46.13%
Net Income, GAAP
- -
30.39%
4.23%
Sales/Revenue/Turnover
- -
16.74%
-15.05%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
201
344
1,178
567
2,290
2025
480
404
679
382
1,945
2026
613
472
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-129
-167
-158
-187.85
-716
2025
-111.49
-195
-142.76
-188.87
-591
2026
-186.87
1,118.5
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Kwon Kim
Full Time Employees
56
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Seoul South Korea
IPO Date
Oct 16, 2024
Business
Cellbion Co., Ltd. is a South Korea-based biopharmaceutical company focused on the discovery, development, and commercialization of precision theranostic radiopharmaceuticals for oncology indications. Founded in 2010 and headquartered in Seoul, South Korea, the company develops targeted radioligand therapies, antibody-radionuclide conjugates, and complementary molecular diagnostic imaging agents leveraging proprietary hydrophilic linker and radiolabeling technologies. The company structures its operations into two primary business segments: Therapeutic Radiopharmaceuticals and Diagnostic Radiopharmaceuticals. Cellbion's core product portfolio and pipeline include 177Lu-DGUL (lutetium (177Lu) pocuvotide satetraxetan), a clinical-stage prostate-specific membrane antigen (PSMA)-targeted therapeutic radioligand designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC); 68Ga-NGUL, a gallium-68-labeled companion positron emission tomography (PET/CT) diagnostic imaging agent engineered for high-affinity PSMA tumor detection with reduced non-target organ uptake; 68Ga-FAP and 225Ac-FAP, preclinical diagnostic imaging and targeted alpha therapy candidates directed against fibroblast activation protein in solid tumors; and novel antibody-radionuclide conjugates utilizing actinium-225 and lutetium-177 radionuclides for refractory cancer targets. The company maintains Good Manufacturing Practice (GMP)-certified radiopharmaceutical production and quality control facilities at the Seoul National University Hospital Cancer Research Institute and a specialized research center in Bundang, serving clinical research institutions, hospitals, and oncology care providers. In October 2024, Cellbion completed its initial public offering and listed its common shares on the KOSDAQ market under ticker symbol 308430. Recent corporate and clinical developments include submitting an application for conditional marketing authorization in South Korea for lead drug 177Lu-DGUL following the conclusion of Phase 2 clinical trials; conducting the collaborative IGNITE trial evaluating 177Lu-DGUL in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda); securing global clinical supply and CDMO manufacturing arrangements with Canada-based Centre for Probe Development and Commercialization (CPDC) and AtomVie Global Radiopharma; and entering into a strategic memorandum of understanding with Ahn-Gook Pharmaceutical Co., Ltd. in September 2026 to jointly research, discover, and develop next-generation targeted radiopharmaceutical therapies.